Author

F. Naeemikia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Shah· 1 shared C. Dong· 1 shared D. M. McCandlish· 1 shared E. O'Brien· 1 shared H. Inam· 1 shared I. Sokirniy· 1 shared J. R. Pritchard· 1 shared Y. Rao· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Shah

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to ALK inhibitors.

H. Inam, I. Sokirniy, Y. Rao, A. Shah, F. Naeemikia, E. O'Brien, C. Dong, D. M. McCandlish, J. R. Pritchard

The paper reanalyzes ALKATI's role in melanoma using genomic and experimental methods, finding it does not predict single-agent ALK inhibitor sensitivity.

bioRxiv · Jun 17, 2021 · PreprintBioengineering